about
Comparative Effectiveness of Biomarkers to Target Cancer Treatment: Modeling Implications for Survival and CostsGenotyping analysis and ¹⁸FDG uptake in breast cancer patients: a preliminary research.Controversial roles of methylenetetrahydrofolate reductase polymorphisms and folate in breast cancer disease.Portrait of inflammatory response to ionizing radiation treatment.Cytokine profile of breast cell lines after different radiation doses.Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification.Expression of Stromal Caveolin- 1 May Be a Predictor for Aggressive Behaviour of Breast Cancer.Radiation-Induced Gene Expression Changes in High and Low Grade Breast Cancer Cell Types.
P2860
Q36614650-0EEB0F34-708C-40EB-8399-5DB4F2F7E23CQ36823340-39900243-38AB-4207-B998-139869408F18Q38260470-CC6CF221-8BB0-4BBA-9D7B-CB6953D2A3A2Q38364169-6F722357-1E86-4075-9037-FDF3E4717C0FQ38649440-DC903D0E-42C2-4AF0-94D8-4AA58D3D0059Q38918710-14E519A1-5D86-438C-9B74-4CB5F2658B07Q51123368-CD3CB5F9-94B2-491E-B06E-FA90EAD30644Q52721717-1C11C907-2A90-44F6-8CC5-7A87A552F501
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
"Omics" of HER2-positive breast cancer.
@en
type
label
"Omics" of HER2-positive breast cancer.
@en
prefLabel
"Omics" of HER2-positive breast cancer.
@en
P50
P356
P1476
"Omics" of HER2-positive breast cancer
@en
P2093
Valentina Bravatà
P304
P356
10.1089/OMI.2012.0099
P577
2013-02-19T00:00:00Z